Great Bay Bio Established its Advisory Board with Two Industrial Leaders

Created on:2019-08-12 10:45


August 12th,2019 Press Release


Great Bay Bio Established its Advisory Board with Two Industrial Leaders


[August 12, 2019-Hong Kong] Great Bay Bio, an AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) and biologics R&D, established its 3D Advisory Board. The Board felt honored to have two industrial elites-Dr. Su Jing and Mr. Wang Yiran join in. They will work together with the Board to provide advice to the senior management team on strategic positioning, product portfolio composition, technical troubleshooting, and general management, etc. More importantly, this 3D Advisory Board will introduce a series of forward-looking concepts from business, scientific research and technology, and offer new and efficient solutions about marketing. The 3D Advisory Board is vital to the company's value positioning. Breakthroughs will be achieved by combining business forecast, scientific research, and technology. At present, the company is forming three independent subcommittees (for business, science and technology), which will lay a solid foundation for the company’s development and ultimately achieve its business mission to make global biologics development easier.

Brief Introduction to Members of the 3D Advisory Board

Dr. Su Jing, member of the science sub-committee. She has nearly 20 years’ experience in new drugs R&D, management and operation. Right now, she is the President and Head of Novo Nordisk Research Center in China. She once led the establishment of Novo Nordisk's new biopharmaceutical R&D department in China and became the head of the department and vice president of global R&D. She is the former Chief Operating Officer of GlaxoSmithKline R&D Center in China and has established a world-leading platform for identifying new drug targets and therapeutic candidates. She is the bachelor of medicine from Peking University Health Science Center, master of BiMBA Business School of Peking University, and Ph.D. of pharmacology from New York University Langone Medical Center.

Mr. Wang Yiran, member of the business sub-committee. Mr. Wang works for a world-renowned venture capital funds as the vice president of investment of an investment advisory agency, responsible for the investment business of Greater China. As an entrepreneur, engineer and investor, he has accumulated multinational working experience in Beijing and San Francisco Bay Area. He is the bachelor of electrical engineering from Peking University, master of electrical engineering from the University of Michigan, and MBA of Harvard University.

When it comes to the establishment of the 3D Advisory Committee and the joining of two industry elites, Mr. Kingsley Leung, Chairman and Co-founder of Great Bay Bio, said: "The joining of Dr. Su Jing and Mr. Wang Yiran is critical to GBB’s development. We feel fortunate and honored to have these two outstanding and talented collaborators join our advisory board. I would like to say that GBB’s strategy is to create a cutting-edge innovative idea, the reconstruction-based innovation. It should not be the simple formal innovation, just breaking the traditional mindsets. It should be the re-fusion of innovations to form a creative system which caters to the new environment and meets customers’ needs. In fact, many current innovations are reconstruction-based ones, such as the first smartphone. Combining previous innovations of different fields and disciplines, the smartphone becomes the device which can change the world. We believe that the best innovation comes from cooperation between people with different backgrounds and expertise, that’s why we established our advisory board. We should cut the high cost of traditional CMC researches, which proves to be quite difficult. We believe that restructuring innovation will be our best choice."


About Great Bay Bio 


Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.

GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.

GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.

The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.



For more details, please

Contact for

Contact for media and investment:

Home    News    Great Bay Bio Established its Advisory Board with Two Industrial Leaders